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A B S T R A C T
Background: It has been demonstrated that postconditioning (postcon), brief episodes of ischemia during
reperfusion period, in patients with ST-segment elevation myocardial infarction (STEMI) confers
protection against ischemia–reperfusion injury and as a result, postcon might reduce infarct size.
However, whether postcon may exert its beneﬁcial effect on STEMI patients by reducing the occurrence
of early malignant ventricular arrhythmias (VA) is still unknown. The aim of the study was to evaluate
the inﬂuence of postcon on the presence of VA in early presenters with high-risk STEMI treated with
primary coronary intervention (PCI).
Methods: Seventy-ﬁve STEMI patients treated with primary PCI within 6 h from symptoms onset were
randomly assigned to postcon group (n = 37) or conventional PCI group (n = 38) in 1:1 ratio. Postcon was
performed immediately after restoration of coronary ﬂow as follows: the angioplasty balloon was
inﬂated 4 1 min with low-pressure inﬂations, each separated by 1 min of deﬂation. After that the
patients were continuously monitored electrographically for 48 h. The end-point of the study was the
occurrence of VA (ventricular ﬁbrillation-VF, sustained ventricular tachycardia-sVT, non-sustained
ventricular tachycardia-nsVT) within 48 h after the procedure.
Results: In the postcon group, the occurrence of VAs was signiﬁcantly lower: VF-3, sVT-0, nsVT-15, i.e.
(18 patients – 48.6%) in comparison to control group: VF-2, sVT-4, nsVT-23 (29 patients – 76.3%);
p = 0.013. The occurrence of accelerated idioventricular rhythm varied insigniﬁcantly between both
groups (postcon – 45.9% vs control – 34.2%; p = NS).
Conclusions: Postcon may reduce the occurrence of malignant VA in patients with STEMI treated with
primary PCI.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Timely and effective reperfusion therapy nowadays plays a
crucial role in the treatment of patients with ST-elevation
myocardial infarction (STEMI) [1]. Early reperfusion with primary
percutaneous coronary intervention (PCI) leads to decreased
morbidity and mortality, by limiting myocardial necrosis expan-
sion [2]. However paradoxically, while salvaging myocardium
from infarction, it may also induce additional myocardial injury* Corresponding author at: 1st Department of Cardiology, University of Medical
Sciences, 1/2 Dluga Street, 61-848 Poznan, Poland. Tel.: +48 608574375;
fax: +48 618549094.
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http://dx.doi.org/10.1016/j.jjcc.2015.02.010
0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardioloand cardiomyocyte death – a phenomenon termed ischemia–
reperfusion injury (IRI) [3,4]. The injury to the heart during
myocardial reperfusion causes four major types of cardiac
dysfunction: myocardial stunning, microvascular obstruction
and no-reﬂow phenomenon, reperfusion arrhythmias, and lethal
reperfusion injury [4,5].
It has been demonstrated that postconditioning (postcon), brief
interruption of coronary blood ﬂow during reperfusion period,
provides protection against IRI [6]. It has been also reported that
postcon might reduce infarct size, no-reﬂow phenomenon, and
microvascular obstruction as well as improve left ventricular
function in STEMI patients treated with primary PCI [7–12]. How-
ever, whether postcon may exert its beneﬁcial effect on STEMI
patients by reducing the occurrence of early malignant ventricular
arrhythmias (VA) is still unknown.gy.
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postcon on the occurrence of VA in early presenters with high-risk
STEMI treated with primary PCI.
Methods
Study population
From October 2010 to December 2013 all patients admitted to
our department who were eligible for a primary PCI due to STEMI
were considered for enrolment on our study, provided they
fulﬁlled the following inclusion criteria: age >18 and <80 years,
chest pain >30 min and <6 h (preferably <4 h, <6 h only if chest
pain persisted and ST-segment elevations), ST segment elevation
>0.1 mV (>0.2 mV in V1–V3) in two contiguous electrocardiogram
(ECG) leads, and a thrombolysis in myocardial infarction (TIMI)
grade 0 ﬂow in the infarct-related artery. The patients were
excluded if they had: previous myocardial infarction, previous
coronary artery bypass surgery, cardiogenic shock, cardiac arrest,
the presence of collateral ﬂow to the infarcted area as evidenced by
a Rentrop score 1, known renal impairment (serum creatinine
>150 mmol/l), persistent atrial ﬁbrillation, ongoing malignant
process, history of gastrointestinal bleeding or stroke, any
contraindication for glycoprotein IIb/IIIa inhibitors, and any
condition that was considered to interfere with the possibility
for the patient to complete the study protocol.
Study design and protocol
This was a prospective, single-center, randomized, controlled,
open–label study with blinded evaluation. The study was
performed according to the provisions of the 1975 Declaration
of Helsinki and good clinical practice. All the participants gave
written informed consent for our investigation. The local ethics
committee approved the protocol of the study (No. 547/11).
Patients were pretreated with aspirin (300 mg orally), clopido-
grel (600 mg orally), and heparin (intravenously at a dose of 60 UI/
kg) before PCI. After hospital admission, coronary angiography was
performed to identify the culprit lesion and assess TIMI ﬂow in
infarct-related artery either antegradely or from collaterals.
Coronary angiography was performed by the percutaneous
technique using the transradial approach in most cases.
Following angiographic data acquisition, patients were random-
ized, using 1:1 sequence placed in numbered sealed envelopes, into
the control or postcon group. After guidewire placement in the
distal part of the vessel, thrombectomy was performed in all
patients. In the control group a drug-eluting stent was subsequently
implanted with direct technique whenever possible. Postcon was
performed by reinﬂating the balloon at the same location to a
pressure 4–6 atm for 60 s starting 1 min after initial reperfusion
with thrombectomy. This cycle was then repeated four times. The
selection of this ischemia–reperfusion sequence was based on
previous experimental and human studies [8,9]. Patients in the
control group received no additional intervention during 4 min of
reperfusion. The procedure was ﬁnished with drug-eluting stent
implantation. Glycoprotein IIb/IIIa inhibitors (abciximab) were
administered in all patients. All patients were treated with aspirin
75 mg daily lifelong and clopidogrel 75 mg daily for 12 months.
Angiographic analysis
Angiographic assessment was performed independently by two
experienced angiographers who were blinded to each other and to
the clinical data. It included TIMI ﬂow grade before and after the
procedure, myocardial blush grade (MBG), and Rentrop’s score of
collateral ﬂow [13].Electrocardiographic monitoring and ECG analysis
All patients were continuously monitored throughout the
procedure and after intervention at intensive cardiac care unit
(48.4  4.3 h). Multilead and computerized arrhythmia detection
system (IntelliVue MP70, Philips, Amsterdam, the Netherlands) was
used. All the data were digitally recorded and then analyzed off-line
with the use of the equipment software by trained cardiologists. The
incidence, length, and time of occurrence of potentially life-
threatening arrhythmias, including ventricular tachyarrhythmias
such as ventricular ﬁbrillation (VF) and sustained and non-sustained
ventricular tachycardia (sVT; nsVT), were studied.
VF was deﬁned as irregular undulations of varying contour and
amplitude on the ECG with absent distinct QRS and T waves and
hemodynamic compromise requiring deﬁbrillation. sVT was
deﬁned as regular wide-complex tachycardia (>110 beats per
minute – bpm) of ventricular origin lasting 30 s and/or
accompanied by hemodynamic compromise requiring electrical
cardioversion or anti-arrhythmic therapy. nsVT was deﬁned as
regular wide-complex self-limiting tachycardia of at least 3 QRS
complexes (RR intervals of <500 ms) and lasting 30 s.
Accelerated idioventricular rhythm (AIVR) was deﬁned as
ventricular wide-complex rhythm with a rate between 40 and
110 bpm.
Atrial ﬁbrillation was deﬁned as completely irregular atrial
rhythm 350–500 bpm (f wave) with irregular ventricular rhythm.
A standard 12-lead ECG tracing was obtained at admission and
30 min after the end of PCI. The sum of ST-segment elevation was
measured manually 60 ms after the end of the QRS complex from
the leads exploring the infarct area. The resolution of ST segment
was calculated as a percentage of the value obtained from basal
ECG. A reduction higher than 70% of the initial value was
considered signiﬁcant [14].
Endpoints
The primary endpoint of the study was the combined incidence
of VF, sVT, or nsVT. The secondary endpoint was the incidence of
AIVR.
Statistical methods
Continuous variables are expressed as mean or median and
categorical data are reported as frequencies and percentages.
Comparisons between groups were performed using unpaired
Student’s t-test or Mann–Whitney U-test for continuous variables
and Chi-square or Fisher’s exact test for categorical variables. A
value of p < 0.05 was considered statistically signiﬁcant.
Considering an expected 20% reduction in the incidence of VAs,
we calculated a total sample size of 68 patients to achieve the
power of the test of 90%.
Results
From a total of 423 screened patients with STEMI, 121 patients
met the initial criteria and had been found eligible for the study,
but 26 were subsequently excluded as shown in Fig. 1. The
remaining 95 patients underwent randomization to postcon and
control groups, but 20 declined participation, which left
75 patients (37 in the postcon group and 38 in the control
group). There were no signiﬁcant differences between groups
with regard to baseline demographic, angiographic, and proce-
dural characteristics (Tables 1 and 2). The peak creatine kinase
(CK), CK-MB, and troponin I levels were signiﬁcantly lower in the
postcon group (Table 1). This group also showed signiﬁcantly
more frequent occurrence of MBG 3 (30 patients, 81.1%) in
Fig. 1. Patient ﬂow diagram. STEMI, ST segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction ﬂow grade; IRA, infarct related artery; postcon,
postconditioning; ECG, electrocardiography; G-I, gastrointestinal.
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p = 0.005. ST-segment resolution was also signiﬁcantly more
frequent in the postcon group – 33 patients (89.2%) vs 25 patients
(65.8%), p = 0.03.Table 1
Clinical characteristics of study groups.
Characteristics Post
n =
Age (years)  SD (median) 56.6  1
Men (%) 25 (67.6
Body mass index (kg/m2)  SD 27.9  4
Diabetes mellitus (%) 6 (16.2
Glycemia on admission (mmol/l)  SD (median) 8.3  2
Obesity (%) 11 (29.7
Hypertension (%) 19 (51.3
Family history of angina pectoris (%) 12 (32.4
Smokers (%) 22 (59.5
Symptoms to balloon time (min)  SD (median) 207.8  8
Systolic blood pressure on admission (mmHg)  SD 146.3  2
Diastolic blood pressure on admission (mmHg)  SD 85.3  1
Heart rate on admission (beats per minute)  SD 73.3  1
Killip-Kimball Class 1 on admission (%) 35 (94.6
Multivessel disease (%) 11 (29.7
Anterior myocardial infarction (%) 11 (29.7
CK baseline (U/I) (mean  SD) 176.6  1
CK-MB baseline (U/I) (mean  SD) 30.1  1
CK peak (U/I) (mean  SD) 2328.8  1
CK-MB peak (U/I) (mean  SD) 252.8  1
Troponin I peak (ng/l) (mean  SD) 68.2  4
Ejection fraction (%) (mean  SD) 50.1  1
Antiarrhythmic drugs
b-blockers (%) 33 (89.2
Amiodarone (%) 5 (15.6
SD, standard deviation; CK, creatine kinase.The evaluation of arrhythmias
In the postcon group the following VAs were observed: VF – in
3 patients, sVT-0 patients, nsVT-27 episodes in 15 patients, totallycon
 37
Control group
n = 38
p
0.5 (56) 56.8  9.9 (57) 0.6
) 30 (78.9) 0.27
.03 (27.8) 28.1  3.02 (27.6) 0.8
) 7 (18.4) 0.5
.7 (7.5) 8.8  4.2 (7.4) 0.9
) 11 (28.9) 0.9
) 22 (57.9) 0.6
) 9 (23.7) 0.4
) 20 (50) 0.6
2.9 (186) 216.9  91.7 (194) 0.17
0.6 145.8  18.4 0.3
0.95 86.5  11 0.32
6.2 (76) 71.2  12.4 (68) 0.8
) 33 (86.8) 0.25
) 17 (44.7) 0.18
) 12 (31.6) 0.9
13 233.7 162.5 0.075
4.4 38.2  30.2 0.08
392.4 3143.2  1352.5 0.003
96.1 343.1  162 0.01
3.1 88.9  34.2 0.03
0.4 46.9 9.3 0.2
) 34 (89.5) 0.63
) 8 (21) 0.29
Table 2
Angiographic characteristics of study groups.
Characteristics Postcon
n = 37
Control group
n = 38
p
Symptoms-to balloon time (min)  SD (median) 207.8  82.9 (186) 216.9  91.7 (194) 0.17
Culprit vessel
LAD (n, %) 11 (29.7) 12 (31.6) 0.86
RCA (n,%) 21 (56.8) 20 (52.6) 0.72
LCx (n, %) 5 (13.5) 6 (15.8) 0.52
Target lesion location
Proximal (n, %) 22 (59.5) 20 (52.6) 0.55
Mid (n, %) 15 (40.5) 18 (47.4) 0.55
Multivessel disease (n, %) 11 (29.7) 17 (44.7) 0.18
Initial TIMI ﬂow 0 (n, %) 37 (100) 38 (100) 1
Final TIMI ﬂow 3 (n, %) 36 (97.3) 33 (86.8) 0.1
Final TIMI ﬂow 2 (n, %) 1 (97.3) 5 (86.8) 0.12
Reference luminal diameter (mm) 3.4  0.3 3.3  0.3 0.81
Thrombectomy 37 (100) 38 (100) 1
Postcon, postconditioning; LAD, left anterior descending artery; RCA, right coronary artery; LCx, circumﬂex artery; TIMI, thrombolysis in myocardial infarction ﬂow
grade; SD, standard deviation.
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group: VF was observed in 2 patients, sVT-6 episodes in 4 patients,
nsVT-39 episodes in 23 patients, totally the incidence of malignant
VAs in control group appeared in 29 patients (76.3%). The
difference in the incidence of VAs between postcon group and
control group was statistically signiﬁcant; p = 0.013, Fig. 2. The
occurrence of AIVR differed non-signiﬁcantly between both groups
– it was observed in 17 patients (45.9%) in postcon group whereas
in control group it occurred in 13 patients (34.2%), p = 0.3.
Timeframe of the occurrence of VAs is shown in
Fig. 3. Generally, the vast majority of incidents of VAs (80% in
postcon group and 78.7% in control group) took place during ﬁrst
12 h after the procedure (Fig. 4).
Atrial ﬁbrillation was observed in only 2 patients (5.4%) in the
postcon, and 3 patients (7.9%) in the control group, p = 0.67.
The peak CK and CK-MB in patients with arrhythmic events
were signiﬁcantly higher (respectively 2423  1293.2 U/l vs
3053  1341.5 U/l, p = 0.01 and 241.7  184.1 U/l vs 353.2 164 U/
l, p = 0.009).Fig. 2. Ventricular arrhythmia episodes in the postconditioning (postcon) and
control groups. VF, ventricular ﬁbrillation; sVT, sustained ventricular tachycardia;
nsVT, non-sustained ventricular tachycardia.Clinical follow-up
One-year follow-up was available for 73 of 75 patients (97.3%).
Overall, four patients died – two in control group (cardiac death)
and two in postcon group (one – cardiac death and one died
because of neoplasm; p = 0.68). Recurrent non-fatal myocardial
infarction was observed in 4 patients (2 in postcon and 2 in control
group, p = 0.68). Clinically driven target vessel revascularization
was necessary in 6 patients (2 in postcon and 4 in control group,
p = 0.35).
Discussion
The major ﬁnding of the present study is that postcon reduced
the occurrence of early malignant arrhythmias in patients with
STEMI. According to our best knowledge the present research is the
ﬁrst randomized study evaluating the impact of postcon on the
incidence of arrhythmias in humans with STEMI.
Postcon was ﬁrst described by Zhao et al. who demonstrated in
canine hearts that interrupting myocardial reperfusion with three
30-s cycles of left anterior descending artery re-occlusion and
reﬂow prevented IRI and reduced myocardial infarct size by 44%
[6]. This therapeutic approach was rapidly translated into clinical
setting of primary PCI by Staat et al. [7]. A number of furtherFig. 3. Time of occurrence of ventricular arrhythmia (VA) episodes during 48 h after
the procedure in the postconditioning (postcon) and control groups.
Fig. 4. An example of non-sustained ventricular tachycardia in a 62-year-old patient after anterior wall ST-elevation myocardial infarction treated with primary percutaneous
coronary intervention 3 h after symptoms’ onset (control group).
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patients including reducing of infarct size, the area of microvascu-
lar obstruction, and no-reﬂow phenomenon, although not all
studies were positive [15–19].
A study on animals reported that an intermittent form of
reperfusion (postcon) markedly reduced the incidence of reperfu-
sion-induced VF following a 20 min episode of coronary artery
occlusion [20]. Several other animal studies support the earlier
results of an anti-arrhythmic action of postcon. Galagudza et al.
reported that a single 2 min global ischemic episode displaying
persistent VF 15 min after reperfusion resulted in deﬁbrillation.
This study was performed on isolated rat hearts [21]. Sasaki et al.
[22] described the inﬂuence of a 5-min global ischemia instituted
1 min after reperfusion to terminate reperfusion arrhythmias in
rats, while Kloner et al. reported that a more classical ischemic
postcon protocol (4 20 s) following a 5-min index episode of
coronary artery occlusion (insufﬁcient to cause necrosis) per-
formed in a rat in vivo reduced the incidence of VT during
reperfusion [23,24]. Our results indicate that postcon attenuates
VAs particularly during the ﬁrst 2 h after the infarct-related artery
recanalization (Fig. 3). It means that postcon inhibits mainly
reperfusion arrhythmias. The detailed mechanisms of their
formation remain unclear. The causes may include heterogeneous
recovery of conduction and the refractory period by incomplete
reperfusion, reentry, abnormal automaticity, activities triggered by
Ca2+ overload, and free radicals [25]. Moreover, it has also been
reported that radical scavengers can inhibit reperfusion arrhyth-
mias [26]. The mechanisms by which ischemic postcon terminates
reperfusion arrhythmia and prevents the recurrence of arrhythmia
may involve the correction of electrical homogenization due to
reduction of Ca2+ overload and free radicals. The details of the
mechanisms, however, are still unclear. Pharmacological inhibi-
tion studies suggest that the effect in rats is not mediated by
adenosine, PI3-kinase, KATP channels, or mitochondrial permeabil-
ity transition pore opening. Further study will be necessary to
investigate which mechanism is responsible for the antiarrhyth-
mic effects of postcon [27]. Okishige et al. studied the
electrophysiological effects of ischemic postcon in a group of31 patients with acute MI treated with primary PCI [28]. In this
observational study the authors found that postcon exhibited
signiﬁcant antiarrhythmic effects which were evaluated by the
change in the QT dispersion.
In our study a high prevalence of patients who experienced VAs
was observed in both groups (45.9% vs 76.3%). Such a high ratio
arrhythmia seems to be considerably higher than in other studies
reported in the literature. The incidence of nsVT (monomorphic) in
the setting of acute MI is usually reported as being between 1% and
7% of STEMI patients although it may be as high as 75% in patients
treated with thrombolysis [29–31]. Cricri et al. observed 7% of life-
threatening arrhythmias in patients with STEMI treated with
primary PCI [32]. In a study carried out by Ohlow et al. only 4.7% of
510 patients who underwent primary PCI for STEMI developed
sustained VAs [33]. The high incidence of VAs in our study is
probably due to the fact that we included high-risk patients who
presented early with a relatively large area of viable myocardium,
which constituted a more pronounced substrate for the develop-
ment of arrhythmias. In the PAMI trial the delay between onset of
symptoms and patients’ arrival in the emergency room was shorter
in subjects who experienced sustained ventricular tachyarrhyth-
mias in the catheterization laboratory than in those who remained
arrhythmia-free [34]. Moreover, in the retrospective cohort study
of patients undergoing PCI for STEMI in New York State, patients
presenting within 6 h after symptom onset were more likely to
experience early, sustained ventricular tachyarrhythmias than
those who presented later [35].
Another explanation of such a high prevalence of VAs in our
study is probably the fact that in most other studies, only the
presence of sVT and VF were assessed.
Opinions on the impact of VAs on clinical outcomes in STEMI
patients undergoing PCI remain controversial. In the PAMI trial
population, no inﬂuence of the occurrence of VF and VT in the
cardiac catheterization laboratory during PCI procedure on in-
hospital or one-year outcomes was observed; at the same time,
mortality seemed to be not at all affected [34]. In contrast, in the
APEX AMI trial, the occurrence of VAs during or after PCI was
associated with an increased, 90-day mortality in STEMI patients,
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Cricri et al., 30-day mortality was signiﬁcantly higher in patients
who had experienced an episode of life-threatening arrhythmia
during hospitalization than in those who had not [32].
We believe that postcon method, which is relatively easy to
apply in clinical practice, can signiﬁcantly reduce reperfusion
injury including the malignant VAs leading to sudden cardiac
death and improve prognosis in STEMI patients. Even the
presence of nsVT might be associated with larger area of necrosis
and stunned myocardium and lead to the worsening of prognosis.
Majidi et al. performed continuous Holter monitoring on patients
with anterior STEMI who had TIMI ﬂow grade 3 following
primary PCI [38]. Subjects with bursts (deﬁned as >3 ventricular
ectopic beats) had higher absolute peak ST segments and more
frequent worsening of ST elevation immediately after reperfu-
sion. Furthermore, these investigators showed that these bursts
correlated with larger infarct size and lower left ventricular
ejection fraction among patients with anterior STEMI with post-
primary PCI TIMI ﬂow grade 3 and ST resolution greater than 50%
[38]. This hypothesis should be, however, conﬁrmed by further
studies.
Study limitations
Undoubtedly, there are some limitations of our study. The
primary limitation was the relatively small number of patients.
Second, only 22.5% of screened patients were initially included and
only 62% of patients meeting the inclusion criteria ﬁnally
participated in the study. However, because postcon has to be
applied within the ﬁrst minute of reperfusion, it is necessary, in a
randomized study such as the present one, to obtain the required
informed consent before the angiography is performed, which,
consequently, leads to a larger screened population than the
potentially angiographic eligible population. The protocol of the
study has a considerable impact on the effectiveness of postcon.
Therefore, when planning the study we had to make sure to
implement an optimal reperfusion therapy. All our patients
received glycoprotein IIb/IIIa inhibitors and had infarct-related
artery opened using aspiration thrombectomy. Direct stenting was
performed whenever possible to avoid microembolization which
could grossly deteriorate the beneﬁcial effects of postcon. Such a
strict protocol obviously excluded potential participants who had a
high risk of bleeding. Despite randomization, as one might expect
in a relatively small study, there are some imbalances in the
baseline characteristics and procedural outcome between study
groups (including baseline CK and CK-MB levels), albeit not
statistically signiﬁcant. However it cannot be excluded that this
contributes to the ﬁndings.
Another limitation is the fact that estimation of infarcted area
was not based on the more advanced methods such as magnetic
resonance, echocardiography, or radionuclide imaging, but only on
peak CK and CK-MB levels.
Clinical signiﬁcance (improvement in prognosis) of postcon has
not been proven in our study. The study was underpowered to
show the potential difference in mortality or in major adverse
cardiovascular events.
Conclusions
In conclusion, the results of the present study indicate that
postcon can signiﬁcantly reduce the occurrence of malignant VAs,
even though the prognostic value of this phenomenon is still to be
investigated. Therefore, further research is necessary to determine
the effect of postcon on the appearance of VAs and the clinical
outcome.Funding
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